Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …

Despite the many advances that have occurred in the field of vaccine adjuvants, there are
still unmet needs that may enable the development of vaccines suitable for more …

Background The humoral immune response after primary immunisation with a SARS-CoV-2
vector vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an …

Subunit vaccines feature critical advantages over other vaccine platforms such as stability,
price, and minimal adverse effects. To maximize immunological protection of subunit …

Abstract Coronavirus disease 2019 (COVID-19) has resulted in millions of deaths globally.
The pandemic has had a severe impact on oncology care and research. Patients with …

Among the currently used COVID-19 vaccines, the mRNA-based vaccines drew the interest
of the scientists because of its potent and versatile nature in mitigating the disease efficiently …

Herd immunity can only be achieved when it is extended to the population level. When a
sufficiently significant fraction of immune individuals exists in a group, it confers indirect …

Vaccine development has become the main tool for reducing COVID-19 cases and the
severity of the disease. Comparative analyses of adaptive immunity generated by different …

To address the need for multivalent vaccines against Coronaviridae that can be rapidly
developed and manufactured, we compared antibody responses against SARS-CoV, SARS …

Restoring everyday civil life from the devastating pandemic of severe acute respiratory
syndrome coronavirus 2 (SARS128; CoV128; 2) can be only by the development of an …